The rising interest in GLP-1 agonists for metabolic conditions has sparked a debate about delivery routes : transdermal systems versus tablets . Typically, GLP-1 drugs were solely available in oral form, https://qasimjvrq506621.blogcudinti.com/41071196/glp-1-transdermal-delivery-systems-vs-tablets-what-right-for-the-patient